Healthcare
Live Price
Offline$17.25
+0.00% today
1Y Change
+56.82%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tsuruha Holdings Inc. (TSUSF) is a Healthcare stock with a market cap of $100.81B and listed on OTC. The stock last traded around $17.25 and up 56.8% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +35.7%, EPS growth of -67.5%, a dividend yield of 2.4%. What stands out right now is revenue +35.7%, EPS -67.5%, free cash flow +34.4% with operating margin 4.3% and ROIC 3.7%. The dividend is present but secondary, with a yield around 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 22.5 and price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TSUSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSUSF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TSUSF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TSUSF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$919.3B
+0.4% YoY
FY Net Income
$26.3B
+22.9% YoY
Free Cash Flow
$61.7B
+383.1% YoY
Revenue Growth
+35.7%
EPS Growth
-67.5%
Gross Margin
30.6%
Net Margin
2.9%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1071.7B | 1027.5B | 970.1B | 915.7B | 919.3B |
| Gross Profit | 326.4B | 312.3B | 293.4B | 271.5B | 266.7B |
| Operating Income | 48.0B | 49.2B | 45.6B | 40.6B | 48.4B |
| EBITDA | 57.4B | 61.2B | 65.2B | 55.2B | 55.2B |
| Net Income | 21.8B | 24.1B | 25.3B | 21.4B | 26.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92.6B | 58.7B | 58.7B | 127.0B | 127.0B |
| Total Assets | 583.4B | 549.2B | 539.8B | 562.4B | 537.0B |
| Total Liabilities | 277.0B | 241.5B | 235.7B | 278.3B | 260.5B |
| Shareholder Equity | 282.1B | 283.9B | 281.6B | 260.3B | 254.6B |
| Total Debt | 63.8B | 50.0B | 54.9B | 55.5B | 55.5B |
| Net Debt | -28.8B | -8.6B | -24.2B | -71.5B | -71.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
76.5B
+113.4% YoY
Capital Expenditures
14.7B
+36.0% YoY
Free Cash Flow
61.7B
+383.1% YoY
Key ratios
Gross Margin
30.6%
Operating Margin
4.3%
Net Margin
2.9%
ROE
9.7%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.